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The completion of the genome sequencing for several organisms has created a great demand for genomic tools that can system-
atically analyze the growing wealth of data. In contrast to the classical reverse genetics approach of creating speciﬁc knockout cell
lines or animals that is time-consuming and expensive, RNA-mediated interference (RNAi) has emerged as a fast, simple, and
cost-eﬀective technique for gene knockdown in large scale. Since its discovery as a gene silencing response to double-stranded
RNA (dsRNA) with homology to endogenous genes in Caenorhabditis elegans (C elegans), RNAi technology has been adapted to
various high-throughput screens (HTS) for genome-wide loss-of-function (LOF) analysis. Biochemical insights into the endoge-
nous mechanism of RNAi have led to advances in RNAi methodology including RNAi molecule synthesis, delivery, and sequence
design. In this article, we will brieﬂy review these various RNAi library designs and discuss the beneﬁts and drawbacks of each
library strategy.
Copyright © 2006 J. Clark and S. Ding.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
RNA-mediated interference (RNAi) provides direct causal
links between speciﬁc genes and observed loss-of-function
(LOF) phenotypes. RNAi is an evolutionarily conserved phe-
nomenon in which gene expression is suppressed by the
introduction of homologous double-stranded RNAs (dsR-
NAs). After dsRNA molecules are delivered to the cytoplasm
of a cell, they are cleaved by the RNase III-like enzyme,
Dicer, to 21- to 23-nt small interfering RNAs (siRNAs) [1].
These siRNA duplexes are loaded into Argonaute2 (Ago2),
the catalytic component of the RNA-induced silence com-
plex (RISC) [2]. Ago2 cleaves the passenger strand of the
siRNA duplex and the antisense strand remains bound to
Ago2. The antisense strand in the now mature RISC serves
as a guide for sequence directed destruction of homologous
mRNA, resulting in silencing of the target gene [3]. In lower
organisms such as Ce l e g a n sand Drosophila, RNAi is typi-
cally induced by the introduction of a long dsRNA (up to 1-
2kb)producedbyin vitro transcription. Although the core
RNAi mechanism appears to be conserved among diverse
organisms, this simple approach cannot be used in mam-
malian cells, where introduction of long dsRNA (> 30nt)
elicits a strong antiviral response that obscures any gene-
speciﬁc silencing eﬀect [4, 5]. Much of this response is
caused by activation of the dsRNA-dependent protein ki-
nase PKR, which phosphorylates and inactivates the trans-
lation initiation factor eIF2a [6, 7]. It was not until the dis-
covery that 21-nt siRNAs could eﬀectively trigger the RNAi
silencing response without activating the antiviral response
that RNAi technology could be developed for mammalian
systems [8].
Originally limited to lower organisms, RNAi technology
has advanced to accommodate a variety of organisms to in-
clude mammals with methodologies that are readily adapted
to high-throughput screens (HTS) [9, 10]. The present avail-
ability of commercial RNAi libraries in addition to advance-
ments in RNAi delivery methods has provided the opportu-
nity for genome-wide screens evaluating any biological path-
way. It is crucial that when deciding on the use of RNAi tech-
nology for the purpose of a genome-wide screen that one
carefully evaluates the characteristics of the selected RNAi
library so that screens can be eﬃciently performed with
excellent gene coverage and highly reproducible data. One
must ensurethatthe RNAilibrary selectedhasbeen designed
to maximize the eﬃciency of gene silencing and that the
method of RNAi molecule delivery is well suited for both
the type of RNAi molecule as well as the system of interest.
The choice of screening an arrayed library or as pools is also
another option that should be carefully considered [11]. In
this article, we will review the current RNAi methodologies
based on the present understanding of the RNAi biochemi-
cal process and brieﬂy discuss developing features in library






















Figure 1: Extracellular generation of siRNA molecules. (a) Sense and antisense strands of RNA are chemically synthesized and annealed
to form 21–23nt or 25–30nt dsRNA molecules. 21–23nt siRNA molecules can directly interact with RISC and guide degradation of the
corresponding mRNA. 25–30nt dsRNA molecules must ﬁrst be cleaved by Dicer to generate the 21–23nt siRNA molecule which can be
loaded into RISC. (b) Recombinant Dicer or RNAse III enzymes can also be used to generate siRNA molecules with silencing capabilities.
21–23nt siRNA molecules are cleaved from dsRNA and associate with the RISC.
Chemicalsynthesis
Initial RNAi libraries were directed solely to invertebrate or-
ganismgenomesandcomprisedoflongdsRNAfragmentsup
to 1-2kb in size, which were generated through in vitro tran-
scription. These long dsRNAs were found to be both highly
speciﬁc and potent inducers of gene silencing in lower or-
ganisms, but the antiviral response in higher mammalian
systems requires a diﬀerent approach [8]. Since the realiza-
tion that siRNAs could avoid the antiviral response while
still eﬀectively triggering a LOF phenotype, many groups
began chemically synthesizing siRNAs. Chemically synthe-
sized RNAi molecules take the form of small duplex RNA
molecules. The sense and antisense strands are synthesized
separately, annealed, and then delivered to cells by such
means as transfection reagents, electroporation, or microin-
jection. Improved understanding of the RNAi mechanism
has resulted in diﬀerent RNAi molecule designs that enter
the RNAi silencing pathway at diﬀerent enzymatic points.
Synthetic siRNA molecules can be designed to interact ei-
ther with Dicer or RISC upon cellular entry (Figure 1(a)).
Initial siRNAs were designed to resemble Dicer products 21–
23nt in size. Dicer product mimics, once transferred into
the system of interest, load to RISC directly and guide the
degradation of homologous mRNA immediately. Kim et al
recently demonstrated that 25–30nt in length RNA duplexes
can more eﬀectively induce gene silencing with up to 100-
fold greater potency than the analogous 21-mer siRNA by
ﬁrstundergoingDicercleavage[12].Kimetalalsonotedthat
some 27-mer duplexes were shown to eﬀectively silence tar-
get regions refractory to the conventional 21-mer siRNA.
Chemically synthesized siRNAs are more widely used in
HTS for the reason of well-characterized reagents, immedi-
ate knockdown of the target mRNA, and high transfection
eﬃciencies compared to that of plasmid-based ones.
Algorithm-baseddesign
InitialsuccessinknockdownwithsmallsiRNAshassinceim-
proved due to greater understanding of the silencing mecha-
nism of Dicer and RISC. The most crucial aspect of an RNAi
library directed at mammalian systems is the choice of the
sequences used to target each gene due to the base pair-
ing speciﬁcity required for precise siRNA targeting and the
diﬀerential silencing potencies of individual siRNAs corre-
sponding to distinct regions of the same mRNA [13]. Ide-
ally, the RNAi molecule must eﬀectively knock down gene
expression while avoiding oﬀ target eﬀects which can be
either sequence-independent or sequence-speciﬁc [14]. As
mentioned above, siRNAs can trigger the mammalian an-
tiviral response inducing translation inhibition or cell death
in a sequence-independent manner [6, 7, 15]. Addition-
ally, sequence similarity to an oﬀ-target transcript can re-
sult in inadvertent degradation [14] or translation inhibition
[16]. Often concentration-dependent, oﬀ-target eﬀects can
beminimizedoravoidedwithminimalsiRNAtreatmentand
the use of unique siRNA sequences, illustrating the need for
eﬀective siRNA sequence design.J. Clark and S. Ding 3
Many commercially available RNAi libraries are de-
signed with siRNA algorithms. The design algorithms for
determining siRNA sequences for mammalian genes are
comprised of a number of parameters based on RNAi bio-
chemical knowledge and empirical data for maximal silenc-
ing eﬃcacy [17]. Some of the most common speciﬁcations
[8, 18–20] include speciﬁc base compositions along the core
siRNA duplex, diﬀerential base-pairing thermodynamics be-
tween the 5’ sense and 5’ antisense strands [20] ensuring ap-
propriate loading of the antisense strand into RISC, A-form
helix formation between siRNA and target mRNA, no in-
ternal repeats or palindromes, 30–50% GC content, and an
absence of close homology to oﬀ-target gene sequences. Se-
quences designed by algorithms based on available genome
sequence data potentially target all predicted genes and
thereforewouldhaveintheorythegreatestgenomecoverage.
The primary deﬁciency of the algorithm-based siRNA
design is our limited understanding of the RNAi mechanism.
Ideally but not practically so far, the eﬃcacy in silencing
endogenously expressed genes by algorithm-designed siR-
NAs in a library would be validated experimentally in cul-
tured cells under strictly standardized conditions. In addi-
tion, the genome-wide RNAi analysis is further restricted to
gene mining technology. Although gene prediction has ad-
vancedgreatlyandprovidesagoodrepresentationofthema-
jority of genes in the genome, not all gene coding sequences
[21] are identiﬁed nor are all possible splice variants pre-
dicted. Reboul et al showed that nine percent of genes iden-
tiﬁed from isolated cDNAs were not predicted by computa-
tionalanalysisofgenomesequences[22].ThematuremRNA
is the target molecule in RNAi and misprediction of gene
boundarieswillreducetheknockdownpotentialofrationally
designed siRNA molecules.
To deﬂect such problems as misprediction and variable
silencing capabilities, many libraries incorporate a degree of
redundancy, using multiple designed siRNA sequences di-
rectedatagene,toincreasethelikelihoodofsilencingthetar-
get gene. Although redundancy would have major implica-
tionsintermsofvariouscosts(eg,siRNAsynthesis,screening
more samples), having multiple siRNA molecules for a par-
ticulargenecanbeadvantageousin thescreenandvalidation
phase, conﬁrming the observed phenotype is the result of si-
lencing of the target gene and not due to an oﬀ-target eﬀect
[23]. The availability of multiple siRNA oligos for each gene
also provides the opportunity to screen as pools of oligos tar-
geting the same gene. In certain scenarios, screening with
such pools may increase the chance of knocking down the
target gene expression eﬀectively and decrease the likelihood
of oﬀ-target eﬀects (due to using lower concentration of
each individual siRNA). Other concerns for synthetic siRNA
libraries are its cost, stability, and nonampliﬁable nature,
which make the generation of siRNA libraries via chemical
synthesis not ﬁnancially practical in individual laboratories.
siRNAsfrommRNAsource
An alternative to algorithm designed synthetic oligos is the
use of pools of siRNAs randomly generated with enzyme-
mediated cleavage of mRNA [13, 24]. The generation of
siRNA cocktails from dsRNA can be accomplished with re-
combinant Dicer [25]o rEscherichia coli (Ec o l i ) RNase III
[26]( Figure 1(b)). Dicer is the enzyme involved in cleav-
ing long dsRNAs into 21–23bp siRNAs in the endogenous
RNAipathway[10].EcoliRNaseIIIcanalsobeusedtocleave
dsRNA into eﬀective siRNAs that are able to directly engage
RISC. The use of Ec o l iRNase III to generate siRNAs may
be preferred due to ineﬃcient in vitro cleavage by Dicer [27].
EitherenzymewillprocessdsRNAsintoapoolofsiRNAstar-
geting multiple sites on the mRNA of interest. Calegari et al
were able to knock down galactosidase expression in the de-
veloping CNS system of day 10 mouse embryos with a com-
plex pool of siRNAs prepared from endoribonuclease diges-
tion (esiRNA) with RNase III [24]. Yang et al were able to
knock down endogenous c-myc protein levels in 293 cells by
70% with esiRNA, as well as Cdk2 expression in a dosage-
dependent manner [27]. The gene silencing eﬀect elicited by
Dicer and RNase III generated pools of siRNA are compara-
ble to well-designed individual siRNAs, but sequence ratio-
nal design is not required.
RNAiexpressionsystems
Model systems such as the Ce l e g a n sand Drosophila are
well adapted to chemically synthesized or mRNA-cleavage-
derived siRNAs due to the presence of an endogenous am-
pliﬁcation of the RNAi signal [1]. In lower organisms, siR-
NAs prime dsRNA synthesis via RNA-dependent RNA poly-
merase (RdRP) where the target mRNA functions as a tem-
plate [28] allowing the generation of new dsRNAs. The C
elegans model system is especially well suited for siRNA si-
lencing not only due to endogenous ampliﬁcation mecha-
nism but also because of the phenomenon of systemic RNAi,
wheregenesilencingcanbeobservedinareasofthebodydis-
tant from the site of the initial dsRNA delivery [29]. Systemic
RNAi is due to a multispan transmembrane protein known
as SID-1, which enables intercellular transport of dsRNA.
This feature is not available in all lower invertebrate organ-
isms and does not exist in Drosophila which has only cell-
autonomous RNAi.
Mammalian systems possess neither endogenous am-
pliﬁcation nor the phenomenon of systemic RNAi, there-
fore the eﬀects of chemically synthesized RNAi molecules
are limited to transient knockdown of the target gene as
a consequence of cell division and/or degradation of the
siRNA molecule. Most HTS experiments require only tran-
sient knockdown to suﬃciently produce an observable phe-
notype. Transient knockdown is insuﬃcient for groups con-
cernedwithbiologicalprocessesrequiringlong-termgenesi-
lencing or for protocols that require some sort of selection.
To address the issue of transient knockdown, many groups
have elected to use intracellular expression of siRNA or short
hairpin RNA (shRNA) molecules from plasmid DNA driven
by either small nuclear RNA (snRNA) U6 or the human
RNase P RNA H1 promoters [30]( Figure 2). U6 and H1
are RNA polymerase III (Pol III) promoters ideally suited













(a) U6 Sense U6 Antisense
(b) U6NNNNNNNNNNNNN H1
(c) U6 Sense Loop Antisense
(d) U6 miR5’ NNNNNN miR3’
Figure 2: Intracellular siRNA molecule generation via plasmids. Dual promoter systems can direct the production of siRNA sense and
antisense strands which anneal and load into RISC. (a) Tandem sense and antisense strands are driven by individual U6 promoters. (b)
A single template transcribes for both the sense and antisense strand via opposing promoter design. (c) The addition of a loop structure
between the sense and antisense template driven by U6 promoter generates shRNA molecules. The shRNA is cleaved by Dicer producing
the functional siRNA molecule. (d) Second-generation shRNA-mir construct is based on miR-30 primary transcript driven by a single U6
promoter. The shRNA-mir molecule is ﬁrst cleaved by Drosha creating an shRNA molecule recognized by Dicer thereby entering the RNAi
mechanism.
elements are located upstream of the transcribed region,
most insert sequences shorter than 400 nucleotides can be
transcribed. The U6 promoter and the H1 promoter have the
same conserved protein-binding sites and transcription ter-
mination sequence, but are diﬀerent in size and identity of
the +1 nucleotide, guanosine for U6, and adenosine for H1
[31].
Lee et al created an siRNA expression vector that tran-
scribes for the sense and antisense strands (Figure 2(a)). The
sense and antisense sequences were located in tandem and
driven by separate U6 promoters. This tandem vector design
wasabletoinduce90%knockdownofEGFPin293cells[32].
They further demonstrated their siRNA expression strategy
to be capable of inhibiting HIV-1 in 293 cells showing up
to 4 logs of inhibition determined via HIV-1 p24 viral anti-
gen levels. To simplify vector construction and expression,
Paul et al created a single promoter system that transcribes
for the sense strand followed by a UUCG tetraloop sequence
followedbytheantisensestrandcreatinganshRNAstructure
[33]( Figure 2(c)). The transcribed shRNA would be cleaved
by endogenous Dicer and generate siRNA molecules capable
of loading to RISC and guide destruction of the homologous
mRNA. Veriﬁcation of their vector-based shRNA expression
was established with the knockdown of the human lamin
A/C in HeLa cells. To further simplify library construction,
a dual promoter siRNA expression vector (pDual) was de-
veloped by Zheng et al that allows the facile construction of
siRNA expression library [34]( Figure 2(b)). The siRNA se-
quence is inserted between opposing U6 and H1 promoters
and serves as the template for both the sense and antisense
strand upon transfection. Zheng’s construct results in an
siRNA duplex with a uridine overhang on each 3’ terminus,
similar to the siRNA generated by Dicer which can be incor-
poratedintotheRISCwithoutanyfurthermodiﬁcation.Fur-
thermore, a simple PCR protocol has been developed that al-
lows an eﬃcient and cost-eﬀective production of siRNA ex-
pression cassettes on a genome scale in a high-throughput
manner.
The vector-based shRNA design strategy was expanded
bygroupsinterested in genome-wideshRNAvectorlibraries.
The shRNA expression construct pools can be generated
from cDNA with restriction enzymes, such as DNase I [35].
Several groups have developed methods to cleave cDNA into
fragments of the appropriate size and quickly clone these
fragments into DNA vectors that generate shRNA structures
in cells [36–38]( Figure 3) .S e v e r a lt e c h n i q u e sh a v eb e e nr e -
ported (REGS [37], EPRIL [38], SPEED [36]) but the un-
derlying principles guiding each are (1) restriction enzyme
(RE) cleavage of cDNA into multiple fragments with nu-
cleotide over hangs, (2) ligation of a 3’ loop with MmeIR E
recognition sequence, (3) further cleavage by MmeIt oc r e -
ate fragments of the requisite size (20-21bp), (4) conversion
of dsDNA fragments into palindromic structures with PCR
ampliﬁcation, and (5) insertion of the randomly generated
sense-loop-antisense sequences into the desired vector back-
bone. Shirane et al showed that their enzymatic production
of RNAi library (EPRIL) generated from cDNA was able to
create shRNAs which could knock down GFP and type 1
inositol 1,4,5-trisphosphate receptor 21 (IP3R) in Jurkat T
























Figure 3: The generation of shRNA libraries from cDNA via enzymatic cleavage.
known and unknown genes across the transcriptome, can be
generated from RE random digests of cDNA libraries [38].
More recently, advanced understanding of microRNA
(miRNA) biogenesis in plants and animals has led to the
construction of a second generation of shRNA expression
libraries, shRNA-mir (Figure 2(d)). These shRNA-mir con-
structs transcribe silencing trigger molecules that mimic the
natural miRNA primary transcripts. Originally believed to
be transcribed from the genome as shRNAs and directly pro-
cessed by Dicer [39], we now believe that miRNAs are ac-
tually transcribed into long primary polyadenylated RNAs
(pri-miRNAs) [40, 41] which are ﬁrst cleaved by Drosha, an
enzyme in the RNase III family, to create pre-miRNAs. The
pre-miRNA is then transported to the cytoplasm, mediated
byExportin-5 [42,43],andonlythenrecognizedandcleaved
b yD i c e rt op r o d u c eam a t u r em i R N A .S i l v ae ta ld e s i g n e d
an shRNA-mir library, based on miR-30 primary transcript
[44], which was shown to be twelve times more eﬃcient than
ﬁrst-generation shRNA expression systems [45].
One added feature of using vector-based si/shRNA ex-
pression system is the facilitation of hit deconvolution by
PCR ampliﬁcation or barcoding when performing selective
screens. Selective screens with vector libraries can be em-
ployed to ﬁsh out the target-speciﬁc and eﬀective sequences
from pools. A pooled shRNA expression library can be intro-
duced into cells while a selective pressure is applied causing
negative control cells to be eliminated from the culture [38].
The selected RNAi sequence in the resistant cells can then
be determined by PCR ampliﬁcation using invariant vector
backbone-based primers. Alternatively, the incorporation of
a gene-speciﬁc sequence into each distinct shRNA vector in
the library is another means of quick identiﬁcation of the
selected gene target. Termed “barcode” screening [46–48],
this identiﬁcation sequence can be located within the vec-
tor backbone [48] or function as the short hairpin sequence
of the shRNA molecule [46]. After the selection event, ﬂuo-
rescent dyes are attached to the barcodes which are then hy-
bridized to microarrays, allowing for the quick identiﬁcation
of positive siRNA sequences within the surviving cell popu-
lation.
In contrast to synthetic siRNAs, the vector-based siRNA
expression systems are ampliﬁable and more cost-eﬀective.
However, their eﬃciency may be compromised in certain
HTS assays. Synthetic siRNAs can directly enter the RNAi
mechanism at the point of Dicer or RISC whereas vector-
based RNAi molecules must ﬁrst be transcribed. In addition,
the transfection eﬃciency of plasmids may be lower relative
to synthetic siRNA oligos, but for cell lines resistant to classic
transfection reagents transduction with viral vectors should
be considered. Furthermore, vector-based stable gene silenc-
ing may be aﬀected by its integration position and result in a
poor knockdown or oﬀ-target eﬀects.
CONCLUSIONAND FUTURE DIRECTIONS
Since the discovery of RNAi, groups have adapted this tech-
nologytosuittheirmodelsystemandassaysofinterest.Afew
new RNAi methodologies recently developed are advances6 Journal of Biomedicine and Biotechnology
in viral delivery systems, incorporation of features such
as inducibility, and ﬂuorescence/selection markers. Several
groups have developed adenoviral RNAi vector strategies
[49, 50] in order to achieve higher levels of transduction and
intracellular expression of the shRNA molecules. Lentiviral
vector approaches have also been reported enabling trans-
duction of the RNAi containing plasmids in nonproliferating
c e l l sa sw e l la sin vivo systems [51–53]. Inducible RNAi vec-
tors have also been developed by several labs as both plasmid
[54–56]a n dr e t r o - / l e n t i v i r a lv e c t o r s[ 57, 58]. RNAi libraries
thatincorporateﬂuorescentmarkershavethebeneﬁtoffacil-
itatingaccurateevaluationoftransfectioneﬃciency.Theseli-
brary design features illustrate the adaptability of RNAi tech-
nology.
RNAi has proven to be a powerful tool in functional ge-
nomics. Its ability to induce the degradation of sequence-
speciﬁc target mRNAs provides a direct relationship be-
tween a gene’s expression level and its functional role [59].
RNAi-based methodologies are suﬃciently robust for HTS
adaptationallowingforgenome-scaleapplications.Advance-
ments aimed at resolving limitations as mentioned above
will no doubt lead to accessibility of cost-eﬀective, validated
genome-wide siRNA collections further advancing our abil-
ity to annotate gene functions and investigate complex bio-
logical processes.
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